

Financial Tear Sheet

Corporate Profile

Perseon is dedicated to developing innovative technologies to fight cancer. Our products treat soft tissue tumors with precision-focused microwave energy, expanding treatment options for patients and healthcare providers everywhere. Backed by a seasoned executive team, we are a market leader in energy ablation, generating growing revenue from our proprietary MicroThermX® line of products.

Primary IR Contact

Tricia Ross


Phone: 310-622-8226

E-mail:

TRoss@finprofiles.com

Stock Performance

PRSN (Common Stock)	
Exchange	NASDAQ (US Dollar)
Financial Status Indicator	C
Price	\$0.07
Change (%)	▼ 0.02 (22.22%)
Volume	148,680
52 Week High	\$7.50
52 Week Low	\$0.07
Market Cap	\$644,577
Rolling EPS	-2.53
PE Ratio	0
Shares Outstanding	9,766,323



Data as of 01/15/16 4:00 p.m. ET

Recent Headlines

12/22/15

[Galil Medical Tender Offer to Acquire Perseon Corporation Expires](#)

11/30/15

[Galil Medical and Perseon Corporation Announce Tender Offer/Merger Information Call](#)

10/27/15

[Galil Medical Enters Into Agreement to Acquire Perseon Corporation to Create Leader in Ablation Treatment for Tumors](#)

SEC Filings

Filing Date	Form
04/27/17	15-12G
01/24/17	EFFECT
01/24/17	EFFECT
01/24/17	EFFECT

Upcoming Events

There are currently no events scheduled.

Corporate Governance

William S. Barth	Chief Financial Officer
Todd H. Turnlund	VP of Research & Design
Jennifer Hoglin	Vice President of Global Marketing
Ben Beckham	Vice President of Global Sales
Brian A. Meltzer, M.D.	Chief Medical Officer and Vice President of Business Development
Rick Gaykowski	Vice President of Regulatory, Quality, and Clinical Affairs

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Perseon 2015.